Christina Vangsted-Hansen

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study

Ralf Reilmann, Andrew McGarry, Igor D. Grachev, Juha‐Matti Savola et autres

de, us, ch, il, it (code pays fourni par la source)

Reduced Cancer Incidence in Huntington’s Disease: Analysis in the Registry Study

Paul McNulty, Richard Pilcher, Renata Necuiniate, Alis Hughes et autres

BACKGROUND: People with Huntington's disease (HD) have been observed to have lower rates of cancers. OBJECTIVE: To investigate the relationship between age of onset of HD, CAG repeat length, and cancer diagnosis. METHODS: Data were obtained from the European Huntington's disease network …

gb, at, de, fr, be, cz, dk, ax, se, fi (code pays fourni par la source)

Clinical manifestations of intermediate allele carriers in Huntington disease

Esther Cubo, María A. Ramos-Arroyo, Saül Martínez‐Horta, Asunción Martínez-Descalls et autres

OBJECTIVE: There is controversy about the clinical consequences of intermediate alleles (IAs) in Huntington disease (HD). The main objective of this study was to establish the clinical manifestations of IA carriers for a prospective, international, European HD registry. METHODS: We assessed a …

es (code pays fourni par la source)